Fig. 8
From: AMPA-ergic regulation of amyloid-β levels in an Alzheimer’s disease mouse model
IL-6 is required for AMPA-R regulation of ISF Aβ levels. Both IL-6−/− mice (n = 5) and C3H/B6 WT mice (n = 6) were treated with 100 μM MK801 for 6 h via reverse microdialysis, then co-treated with MK801 and 7.5 μM AMPA for an additional 17 h. The last five hours of each treatment (MK801 alone vs MK801 + AMPA) were averaged for each treatment group and compared (two-way ANOVA, Sidak post hoc test). In WT animals, ISF Aβ levels decreased by 67.34% from MK801 alone to MK801 + AMPA (p = 0.002). In IL-6−/− animals, the addition of AMPA resulted in a non-significant decrease in ISF Aβ levels of 23.96% (p = 0.652). Furthermore, ISF Aβ levels IL-6−/− mice following extended AMPA treatment are significantly higher than observed in WT mice (80.26 and 23.0%, respectively; p = 0.027). Data plotted as mean ± SEM